Potential antibody therapy restricts the growth of aggressive and treatment-resistant breast cancers
A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.
Oncology & Cancer
A less invasive, more effective method to analyze immunotherapy efficacy
Immunotherapy has been one of the most promising advancements in cancer treatment. However, consistency in immunotherapy treatment effectiveness remains a formidable challenge. Now, Cancer Center at Illinois member Kun Wang, Binbin Wang, a post-doctora…
Immune cell pockets found in lymphoma tumors offer new targets for personalized therapies
By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD Anderson Cancer Center have identified seven distinct cellular microenvironments, providing a framework to develop therapies that w…
Existing drugs for tissue scarring could help avert melanoma relapses
Cellular changes that appear during melanoma and lead to treatment resistance can be reversed with drugs—potentially opening the door to new or more effective treatments for the deadly disease, according to new Cornell research.
Elironrasib may overcome resistance to prior KRAS G12C inhibition in non-small cell lung cancer
Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in the presence of features linked to KRAS inhibitor res…
Zenocutuzumab shows clinical benefit in rare bile duct cancer
Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, according to results from the…
Investigational antibody-drug conjugate shows clinical benefit against previously treated small cell lung cancer
Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce anticancer responses in patients with extensive-stage small cell lung …
New targeted therapy shows promise for patients with advanced bladder cancer
FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs of clinical benefit in patients with advanced urothelial carcinoma, according to results from a phase…
Scientists develop one-product-fits-all immunotherapy for breast cancer
Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.
MTAP-deficient cancer cells share signals that silence immunity
China Medical University leads a multi-institution team reporting that MTAP deficiency suppresses cytosolic nucleic acid sensing and drives resistance to STING agonists, with an existing drug, DFMO, restoring pathway activity and antitumor responses.